Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leuvectin Vical Inc.

A Kaushik1

  • 1Department of Pathobiology, University of Guelph, Ontario, Canada. Akaushik@uoguelph.ca

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Vical

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virome.

British dental journal·2023
Same author

STRINGS.

British dental journal·2023
Same author

Correction to: Citation context.

British dental journal·2023
Same author

Citation context.

British dental journal·2023
Same author

Preprint Citation Index.

British dental journal·2023
Same author

Detection of gut and mucosal peptides through TOMAHAQ in healthy individuals.

Allergy·2023
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Oncology
  • Gene Therapy
  • Immunotherapy

Background:

  • Leuvectin is an investigational gene therapy utilizing plasmid DNA encoding interleukin-2 (IL-2).
  • It is formulated with a lipid delivery vehicle (DMRIE/DOPE) for intratumoral injection.
  • Leuvectin is being developed for cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of Leuvectin as a gene therapy for cancer.
  • To assess Leuvectin's potential in treating kidney and prostate cancers.

Main Methods:

  • Phase II clinical trials were conducted for kidney and prostate cancer.
  • Intratumoral injection of Leuvectin was the primary administration route.
  • Development focused on gene-based, non-viral delivery of IL-2.

Related Experiment Videos

Main Results:

  • Phase II trials for kidney cancer were ongoing, with a discontinuation and replanning in 2001.
  • Prostate cancer trials were ongoing as of May 2001.
  • Development for other indications was suspended to prioritize promising cancer types.

Conclusions:

  • Leuvectin development for cancer gene therapy is ongoing, with a focus on specific indications.
  • The non-viral delivery of IL-2 via Leuvectin has received patent protection.
  • Clinical trial progress indicates continued investigation into its therapeutic potential.